Project Grant R01EY038190
Award Date 4/1/26
Completion Date 3/31/31
Dollars Obligated $663K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
- Federal Project Grant Award Summary The National Eye Institute (NEI) awarded $173,016 to the Whitehead Institute for Biomedical Research under the Vision Research program (CFDA 93.867) for a project grant effective August 1, 2025, through July 31, 2027. This award supports systematic identification and mechanistic characterization of novel oxidative protective genes to prevent retinal pigment epithelium (RPE) degeneration in age-related macular degeneration (AMD). The research involves...
- Federal Grant Award Summary The National Eye Institute (NEI) awarded The Schepens Eye Research Institute, Inc. a Project Grant of $423,866 under the Vision Research program (CFDA 93.867) to develop mini-USH2A gene therapy for treating Usher Syndrome Type 2A (USH2A), the most common inherited condition causing combined hearing and vision loss. The research project, which commenced May 1, 2026 and concludes April 30, 2028, focuses on creating a functional minigene construct that addresses the...
- Federal Grant Award Summary The National Eye Institute (NEI) awarded a $435,052 Vision Research (CFDA 93.867) Project Grant to the University of Massachusetts Boston for the period July 1, 2025 through June 30, 2029. This research project will investigate the molecular and genetic mechanisms that control photoreceptor subtype specification for color vision in the fruit fly (Drosophila melanogaster) retina as a model system. The research will identify conserved transcription factors and...
- Federal Project Grant Award Summary The National Eye Institute (NEI) awarded The Schepens Eye Research Institute, Inc. a Project Grant of $545,948 under the Vision Research program (CFDA 93.867) to advance understanding of glaucoma pathophysiology. The award, effective April 1, 2026 through March 31, 2030, supports research investigating the role of reactive astrocytes in glaucoma progression and retinal ganglion cell (RGC) survival. The research aims to move beyond traditional neurocentric...
- Federal Project Grant Award Summary This $132,837 project grant, awarded on May 1, 2026, by the National Eye Institute under the Vision Research program (CFDA 93.867), funds research investigating SARM1 as a therapeutic target for two hereditary optic neuropathies: Autosomal Dominant Optic Atrophy (ADOA) and Leber Hereditary Optic Neuropathy (LHON). The research, conducted at Boston Children's Hospital in Massachusetts through April 30, 2028, aims to develop a novel therapeutic approach...
- Federal Grant Award Summary Boston Children's Hospital received a $136,512 Project Grant from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867) effective July 1, 2025, through June 30, 2027. The award supports research investigating how intrinsically photosensitive retinal ganglion cells (ipRGCs) transform light information in melanopsin pathways to regulate physiological and behavioral responses. The research employs advanced imaging techniques to measure...
- Federal Project Grant Award Summary Award Details: The National Eye Institute (NEI), under the Vision Research program (CFDA 93.867), awarded a $504,304 Project Grant to Tufts University School of Medicine on April 15, 2026, with a project completion date of March 31, 2031. The award supports research investigating the mechanistic basis of the gut-retina axis and its relationship to age-related macular degeneration (AMD) prevention. Research Products and Services: The project will deliver...
- Federal Grant Award Summary Fannin Partners LLC received a $600,032 Project Grant from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867), effective September 1, 2025 through August 31, 2026. The award funds development of SCG3 raptamers—modified single-stranded DNA aptamers designed as a novel targeted therapy for wet age-related macular degeneration (AMD). The therapeutic approach targets secretogranin III (SCG3), a newly identified angiogenesis and vascular...
- Federal Grant Award Summary Massachusetts General Hospital received a $453,750 Project Grant from the National Eye Institute (NEI) Vision Research program (CFDA 93.867), awarded September 1, 2025, with completion targeted for August 31, 2027. The project, titled "Finessing the Details: Subclasses of LGN Neurons and the Richness of Spatial Transcriptomics," applies spatial transcriptomics technologies to map the spatial distribution and genetic characteristics of neuronal cell types...
- Summary of Federal Project Grant Award The University of North Carolina at Chapel Hill received a $603,053 Project Grant from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867), awarded April 15, 2026, with completion targeted for March 31, 2030. This award supports preclinical development of a gene augmentation therapy for IMPG2-associated retinal degeneration, a genetic condition causing juvenile-onset rod-cone dystrophy and adult-onset vitelliform macular...